Tagged: Alpharadin

Bayer and Oslo-based Algeta enter global agreement

Bayer Schering Pharma, Germany, has entered into a global agreement with Algeta ASA, Oslo, Norway, for the development of the cancer drug Alpharadin. Alpharadin is currently being evaluated in a global phase III trial...

Algeta raises USD 35 million in a Private Placement

Oslo Feb. 18 – Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that it has raised USD 35 million (NOK 245 million) through the Private Placement of 22.3 million new shares, with a...